| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.075 | 0.02 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.02 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.02 |